Biological Information

Background Information:

TRAF6 is an E3 ubiquitin ligase and signalling adaptor that mediates innate and adaptive immune responses by assembling Lys63?linked polyubiquitin scaffolds, which recruit kinases and activate downstream pathways. It functions downstream of multiple receptor families with immunoregulatory functions, including members of the TNFR superfamily, the TLR family, IL?17R and TCR, where K63 ubiquitin chains enable assembly of signalling complexes that activate TAK1, IKK and MAPKs, leading to NF?kappaB and AP?1 transcriptional programs essential for inflammatory and immune signalling. Overexpression of TRAF6 as well as enhanced TRAF6 activity have been shown to promote chronic immune stimulation in a variety of disorders, including autoimmunity, inflammation, and cancer. For example, it has been demonstrated that TRAF6 expression is elevated in rheumatoid arthritis and lupus. Additionally, TRAF6 has been shown to promote CTLA-4 degradation and is a potential therapeutic target for the improvement of T-cell-based cancer immunotherapies.

Target Class:

Ubiquitination-related

Family:

TRAF

Sub Family:

E3 Ligase

Protein Name:

TRAF6

Protein Aliases:

RNF85

Accession Number:

BC031052.1

UniProt Number:

Q9Y4K3

Gene Name:

TRAF6

Gene ID:

7189

Gene Aliases:

RNF85; MGC:3310

Target Species:

Human

Usage

Product Type:

Enzymes

Application:

Drug Discovery & Development

Storage Conditions:

1 year at -70°C

Usage disclaimer:

These products may be covered by issued US and/or foreign patents, patent applications and subject to a Limited Use Label License. Please visit discoverx.com/license for a list of products that are governed by limited use label license terms and relevant patent and trademark information.

Assay Information

Assay Type:

Enzymatic

Assay Measures:

ECL

Bioassay Data

Trademark Statement:

For Research Use Only

Clinical Relevance

Therapeutic Area:

Oncology/Immuno-Oncology/Inflammation